Loading…
Scholar Rock Holding Corporation is projected to rise to $72.17 by 2027, a +43% move from its current price of $50.64. SRRK is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $49.48 | $50.66 | $51.88 | +0.05% |
| May 30 | $49.02 | $50.69 | $52.42 | +0.10% |
| May 31 | $48.67 | $50.72 | $52.84 | +0.15% |
| Jun 1 | $48.39 | $50.74 | $53.21 | +0.20% |
| Jun 2 | $48.14 | $50.77 | $53.53 | +0.25% |
| Jun 3 | $47.92 | $50.79 | $53.83 | +0.30% |
| Jun 4 | $47.72 | $50.82 | $54.11 | +0.35% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $47.72 | $50.82 | $54.11 | +0.35% |
| Week 2 | $46.66 | $50.99 | $55.73 | +0.69% |
| Week 3 | $45.89 | $51.17 | $57.05 | +1.04% |
| Week 4 | $45.28 | $51.34 | $58.22 | +1.39% |
| Week 5 | $44.77 | $51.52 | $59.29 | +1.74% |
| Week 6 | $44.33 | $51.70 | $60.30 | +2.09% |
| Week 7 | $43.93 | $51.88 | $61.26 | +2.45% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company uses a proprietary platform to develop monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors within the transforming growth factor beta (TGFß) superfamily.
Founded in 2012 and headquartered in Cambridge, Massachusetts, Scholar Rock is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies.
The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. The company’s pipeline includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corporation (SRRK) currently trades at $51.51 per share, with a market capitalization of $6.17B and a rank of 1208. The near-term outlook for 2026 is neutral, with an average forecast price of $51.51 and a 30-day range that reflects modest movement around this level. Longer-term forecasts indicate bullish upside, evidenced by a rising average price from 2027 onward.
By 2027 the average forecast price is $74.28, and by 2030 it is $102.68, signaling meaningful upside over the coming years. The forecast also shows continued strength into the mid-2030s and beyond, with 2040 average at $278.05 and 2050 average at $529.84, alongside substantial ROIs of 439.8% by 2040 and 928.6% by 2050. The overall outlook remains bullish through the late horizon, with 2026 marked as neutral before the longer-term uptrend takes hold.
A major floor 21.4% below — a decisive break under it would weaken the trend.
The nearest floor, 8.6% below — buyers have tended to step in here.
Price is pressing into resistance (1.7% away) — a breakout level to watch.
A major ceiling 8.0% above — clearing it would confirm fresh momentum.
Key SRRK support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SRRK market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $49.28 | Buy | $49.73 | Buy |
| MA 10 | $49.21 | Buy | $49.16 | Buy |
| MA 20 | $48.23 | Buy | $48.62 | Buy |
| MA 50 | $47.43 | Buy | $47.57 | Buy |
| MA 100 | $46.24 | Buy | $45.80 | Buy |
| MA 200 | $41.08 | Buy | $42.44 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.92 | Neutral |
| Stoch RSI (14) | 58.57 | Neutral |
| CCI (20) | 121.66 | Buy |
| Williams %R (14) | -17.19 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 4.65 | Buy |
| Bollinger %B (20,2) | 0.88 | Neutral |
| Stochastic %K (14) | 82.81 | Sell |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 0.98 | Buy |
| Ultimate (7,14,28) | 57.84 | Neutral |
| Momentum (10) | 1.45 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 50.08 | Buy |
| ADX (14) | 11.63 | Neutral |
| ATR (14) | 0.99 | Info |
The 30-day range is $43.91 to $60.43. The RSI (14) is 60, and the price is above the SMA50 at $47.22 and the SMA200 at $40.99. The immediate support is $46.29 and the near-term resistance is $51.51.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $39.79 | $50.64 | $71.22 | 0% | Neutral | |
| $57.96 | $72.17 | $94.75 | +43% | Bullish | |
| $63.32 | $80.70 | $109.35 | +59% | Bullish | |
| $72.17 | $93.77 | $130.30 | +85% | Bullish | |
| $74.87 | $98.96 | $140.47 | +95% | Bullish | |
| $75.30 | $101.10 | $146.22 | +100% | Bullish | |
| $87.17 | $118.76 | $174.68 | +135% | Bullish | |
| $99.48 | $137.39 | $205.20 | +171% | Bullish | |
| $112.98 | $158.07 | $239.45 | +212% | Bullish | |
| $123.76 | $175.30 | $269.06 | +246% | Bullish | |
| $174.42 | $261.22 | $423.79 | +416% | Bullish | |
| $301.32 | $496.07 | $873.16 | +880% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $39.79 | $50.64 | $59.73 | +0.00% |
| June 2026 | $45.06 | $52.77 | $63.16 | +4.22% |
| July 2026 | $44.90 | $52.97 | $64.14 | +0.37% |
| August 2026 | $45.69 | $54.21 | $66.24 | +2.33% |
| September 2026 | $47.38 | $56.47 | $69.52 | +4.19% |
| October 2026 | $47.39 | $56.73 | $70.31 | +0.45% |
| November 2026 | $46.47 | $55.85 | $69.62 | -1.56% |
| December 2026 | $47.11 | $56.82 | $71.22 | +1.74% |
Click any year to see its month-by-month SRRK forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, SRRK is projected to trade between $39.79 and $71.22, averaging $50.64 — a potential gain of 0% from today's $50.64. A consolidation phase looks the most probable path here.
Scholar Rock Holding Corporation's 2027 outlook centres on $72.17, within a $57.96 to $94.75 range. That is up +43% on the projected 2026 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2028, SRRK could reach as high as $109.35, with a base case around $80.70 and support toward $63.32 — roughly +59% from $50.64. Buyers look set to stay in control over this stretch.
Expect SRRK to range from $72.17 to $130.30 through 2029. The $93.77 average target implies a +85% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The SRRK price prediction for 2030 points to an average of $98.96 (low $74.87, high $140.47) — a potential gain of +95% on today's $50.64. Buyers look set to stay in control over this stretch.
In 2031, SRRK is projected to trade between $75.30 and $146.22, averaging $101.10 — a potential gain of +100% from today's $50.64. That is up +2% on the projected 2030 average. Momentum favours further upside here.
Scholar Rock Holding Corporation's 2032 outlook centres on $118.76, within a $87.17 to $174.68 range. That is up +17% on the projected 2031 average. That marks a +135% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, SRRK could reach as high as $205.20, with a base case around $137.39 and support toward $99.48 — roughly +171% from $50.64. Momentum favours further upside here.
Expect SRRK to range from $112.98 to $239.45 through 2034. The $158.07 average target implies a +212% move from current prices. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The SRRK price prediction for 2035 points to an average of $175.30 (low $123.76, high $269.06) — a potential gain of +246% on today's $50.64. Momentum favours further upside here.
In 2040, SRRK is projected to trade between $174.42 and $423.79, averaging $261.22 — a potential gain of +416% from today's $50.64. That is up +49% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Scholar Rock Holding Corporation's 2050 outlook centres on $496.07, within a $301.32 to $873.16 range. That is up +90% on the projected 2040 average. That marks a +880% change versus current levels. Momentum favours further upside here.
Investing $1,000 in SRRK today (≈ 19.747235 SRRK) could be worth
$9,795.93
+$8,795.93 (+880%) by 2050 · US Dollar
Based on the average projected SRRK price of $496.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SRRKwould be worth at today's price.
$1,000 invested in SRRK on May 27, 2025 (≈ 32.819167 SRRK) would be worth
$1,661.96
+$661.96 (+66.2%) today · 1.66× · US Dollar
Based on a SRRK entry price of $30.47 vs. today's $50.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $48.38 | $1,046.71 | +4.7% |
| 1 month ago | $46.29 | $1,093.97 | +9.4% |
| 3 months ago | $44.84 | $1,129.35 | +12.9% |
| 6 months ago | $44.06 | $1,149.34 | +14.9% |
| 1 year ago | $30.47 | $1,661.96 | +66.2% |
| All time (5.0y) ago | $27.22 | $1,860.4 | +86.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SRRK forecast.
Our base-case forecast reaches $100.00 around 2031.
Implied market cap at $100.00: $11.98B
The multi-year forecast paints a bullish trajectory after a neutral near term. The 2026 average is $51.51 with a neutral sentiment, followed by rising averages in subsequent years: 2027 $74.28, 2028 $83.24, 2029 $97.19, 2030 $102.68, 2031 $105.06, 2032 $124.30, 2033 $144.32, 2034 $166.26, and 2035 $184.91. By 2040 the average is $278.05 and by 2050 it reaches $529.84, with ROIs of 439.8% and 928.6% respectively.
Sentiment shifts to bullish from 2027 onward and remains so through 2050, reflecting a protracted upside path despite near-term uncertainty.
Tap a question to reveal the answer.
Avg $102.68; min $77.44; max $146.29; ROI 99.3%; sentiment BULLISH. These are estimates and not a guarantee.
Forecasts show a bullish trajectory from 2027 onward with rising averages and a 2030 ROI of 99.3%. Near term (2026) is neutral, with longer horizons showing upside up to 2040 (ROI 439.8%) and 2050 (ROI 928.6%). These are estimates and not guarantees.
No. The 2028 max forecast is $113.14, well below $150.
Low $43.91; high $60.43.
Avg $278.05; min $184.51; max $453.70; ROI 439.8%; sentiment BULLISH.
Scholar Rock Holding Corporation Community Discussion
0Share your Scholar Rock Holding Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.